Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Coronary Heart Disease (Stable Angina) - A therapy that reduces plaque volume (as measured by IVUS) by more than atorvastatin at 18 months 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
Glioma (High Grade) - A therapy that, when added to temozolomide, increases median overall survival compared to temozolomide alone in newly diagnosed glioblastoma patients 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
NSTEMI - A therapy that reduces mortality more than bivalirudin at 30 days 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
Chronic Lymphocytic Leukemia (Relapsed/Refractory ) - A therapy that increases overall response rate compared to alemtuzumab for high-risk, relapsed/refractory patients 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
STEMI - A therapy that is an antiplatelet agent that administered with stenting reduces mortality more than abciximab at 30 days 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
Attention-Deficit/Hyperactivity Disorder - A nonstimulant therapy approved for adult ADHD with no risk of suicidal ideation 3/1/2009 \| published by: Decision Resources ... a comparator drug on key measures of efficacy, safety and tolerability, and delivery. The profiles also provide physician insight on estimated uptake and use (i.e., patient share) of drugs matching the Target Product Profiles as ... \| more...	$9,200.00
Cognitive Impairment Associated with Schizophrenia - A therapy that is formally approved for the treatment of cognitive impairment in schizophrenia 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
Atopic Dermatitis - A therapy that is a topical agent with a novel mechanism of action 3/1/2009 \| published by: Decision Resources ... attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor's. Examples of how to use the information you will find in this report are highlighted below: For companies ... \| more...	$9,200.00
SPECIAL REPORT: State of the Pharmaceutical Industry, 2009 2/24/2009 \| published by: Decision Resources ... longer-can be healthy. It can motivate companies to move, kicking and screaming, away from the status quo to become streamlined, refocused businesses better able to succeed in future markets. This reality is not the hand ... \| more...	$9,200.00
Narrowing the Innovation Gap with Fragment-Based Drug Discovery and Design 2/18/2009 \| published by: Decision Resources ... could make a signifi cant difference in the productivity of drug discovery programs and help to lower their cost. Get the Answers You Need to Shape Your Strategy Pharmaceutical companies are seeking new technologies to ... \| more...	$4,600.00
Market Access, Pricing, and Reimbursement News in the Fourth Quarter of 2008 1/30/2009 \| published by: Decision Resources ... new ways to contain the cost of innovative medicines. To remain successful, pharmaceutical companies must respond positively to evolving cost-containment strategies in each market. Get the Answers You Need to Shape Your Strategy The recession ... \| more...	$4,600.00
Are There Changes Ahead for the Generalized Anxiety Disorder Market? 1/26/2009 \| published by: Decision Resources ... generic players, creating a diffi cult environment for launching new agents. Nonetheless, several emerging agents are set to challenge current market leaders. Get the Answers You Need to Shape Your Strategy GAD can be very ... \| more...	$4,600.00
Special Report: Lessons Learned: Top Events Impacting the Pharmaceutical Industry in 2008 12/22/2008 \| published by: Decision Resources ... announcements, it ended amid a global economic downturn and credit crisis not seen in our lifetime. Change is inevitable-productive change is even better. Although some company leaderships may have been reluctant to alter the status ... \| more...	$9,200.00
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways 12/17/2008 \| published by: Decision Resources ... rate of cancer mortality (more than 500,000 estimated deaths in 2008 in the United States) points to the limitations of these treatment options and highlights the unmet need for the development of more-effective cancer treatments. ... \| more...	$4,600.00
It’s All About the Biomarkers: How 2008’s Biomarker-Based Partnering Is Driving Personalized Medicine 12/17/2008 \| published by: Decision Resources ... Novel technologies, targeted therapies, companion diagnostics, validating biomarkers, standardizing processes, and the mere need for innovation are some of the factors that are compelling these stakeholders to collaborate. Biomarkers-characteristics that are objectively evaluated as indicators ... \| more...	$4,600.00
Emerging Blockbusters: 2009’s Most Promising Drugs and the Future of the Blockbuster Model 12/16/2008 \| published by: Decision Resources ... and growth of the pharmaceutical industry, and the number of blockbusters on the market has continued to rise steadily. However, the disappointing performance of anticipated blockbusters, such as Pfi zer's Exubera (inhaled insulin), inevitably prompts ... \| more...	$4,600.00
Autoimmune Disease Series: Strategies for Success in the Challenging Sjögren’s Syndrome Market 12/16/2008 \| published by: Decision Resources ... develop life-threatening symptoms and complications, including renal or liver failure and B-cell lymphoma. At this time SS has no cure, and treatment is focused primarily on the alleviation of symptoms and the prevention of long-term ... \| more...	$4,600.00
U.S. Pharma Pricing Strategies: Case Studies and Future Considerations 12/9/2008 \| published by: Decision Resources ... without constraints like those found in other markets (e.g., reference pricing in Germany) gives manufacturers the latitude to experiment with pricing strategies after key events (e.g., the entrance of a less expensive generic version of ... \| more...	$4,600.00
What to Do When the R&D Pipeline Runs Dry 12/9/2008 \| published by: Decision Resources ... of the discussion has focused on dispensing with the blockbuster model, which may or may not be outdated, while acknowledging that instituting new models in place of old ones will not be straightforward or easy. ... \| more...	$4,600.00
Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis? 12/5/2008 \| published by: Decision Resources ... agents and the relatively benign nature of the disease, the market for reactive arthritis therapies is limited. Nonetheless, the treatment of chronic and refractory reactive arthritis remains a target for drug development. How promising a ... \| more...	$9,200.00
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008 12/4/2008 \| published by: Decision Resources ... innovative drugs. However, the pharmaceutical industry will be expected to adapt to a more fl exible pricing environment. In this report, we analyze the potential impact of the changes unveiled in November 2008. Get the ... \| more...	$4,600.00
Pricing and Reimbursement of Fixed-Dose Combination Drugs in the United States 12/3/2008 \| published by: Decision Resources ... offer pharmaceutical companies a relatively easy and inexpensive way to bring new drugs to market. However, new surveys of 40 managed care organization (MCO) medical/pharmacy directors and more than 400 physicians, together with a detailed ... \| more...	$4,600.00
What Is the Future Role of Predictive Safety Biomarkers in Drug Development? 12/3/2008 \| published by: Decision Resources ... validation. The role of predictive safety biomarkers in the drug development paradigm is essential in today's cautious and budget-sensitive environment because pharmacogenomic biomarkers are paramount to informing decisions of patient eligibility for drug treatment, potential ... \| more...	$4,600.00
Meeting the Challenges of Manufacturing Biosimilars 11/25/2008 \| published by: Decision Resources ... but could pass in 2009, and President-elect Obama supports establishing a biosimilars regulatory framework. Complex manufacturing issues pose some of the most signifi cant challenges to companies seeking to compete in this potentially lucrative market. ... \| more...	$4,600.00
Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing 11/24/2008 \| published by: Decision Resources ... innovative drugs. However, the pharmaceutical industry will be expected to adapt to a more fl exible pricing environment. In this report, we analyze the potential impact of the changes unveiled in November 2008. Get the ... \| more...	$4,600.00

< prev 4 5 6 7 8 9 10 11 12 13 next >